Lung Cancer Trial, Recruiting (NCT06923098)

Lung Cancer Trial, Recruiting NCT06923098 Sponsor: All India Institute of Medical Sciences, Bhubaneswar Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06923098 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People whose blood clotting levels (INR) are below 1.2 and whose platelet count is above 80,000 per mm³ (these are measures of how well the blood clots)
People who have a spot or growth in the lung larger than 10mm, seen on a chest CT scan
People whose lung lesion is in a position where a CT-guided needle biopsy can safely reach it

Who may not be able to join:

People who have a pre-existing bleeding or clotting disorder (such as hemophilia), or whose blood test results show an INR of 1.2 or higher, or a platelet count of 80,000 per mm³ or lower
People who do not wish to give their consent to participate
People showing signs that their body is not getting enough blood flow, such as low blood pressure or a bluish colour to the skin
People whose blood oxygen level is below 94%, as measured by a finger pulse oximeter
People who are pregnant or currently breastfeeding
People who are unable to cooperate during the procedure
People whose lung lesion is in a position that cannot be safely reached for a biopsy (this decision is made during pre-biopsy planning)
People whose blood creatinine level (a measure of kidney function) is above 2mg/dl

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06923098

Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06923098

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People whose blood clotting levels (INR) are below 1.2 and whose platelet count is above 80,000 per mm³ (these are measures of how well the blood clots)
People who have a spot or growth in the lung larger than 10mm, seen on a chest CT scan
People whose lung lesion is in a position where a CT-guided needle biopsy can safely reach it

Who may not be able to join:

People who have a pre-existing bleeding or clotting disorder (such as hemophilia), or whose blood test results show an INR of 1.2 or higher, or a platelet count of 80,000 per mm³ or lower
People who do not wish to give their consent to participate
People showing signs that their body is not getting enough blood flow, such as low blood pressure or a bluish colour to the skin
People whose blood oxygen level is below 94%, as measured by a finger pulse oximeter
People who are pregnant or currently breastfeeding
People who are unable to cooperate during the procedure
People whose lung lesion is in a position that cannot be safely reached for a biopsy (this decision is made during pre-biopsy planning)
People whose blood creatinine level (a measure of kidney function) is above 2mg/dl

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

All India Institute of Medical Sciences, Bhubaneswar

Registry

ClinicalTrials.gov

Start date

1 July 2023

Est. completion

1 July 2025

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Inconclusive pathology findings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov